India's Arch on the block; seeks strategic investor
This article was originally published in Scrip
The Indian intermediates and active pharmaceutical ingredients (API) manufacturing firm, Arch Pharmalabs, is on the block – apparently coming full circle from the heady days when it drew significant private equity interest to when it saw key investor Japan's Mitsui & Co quietly exit, apparently for a song.
You may also be interested in...
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.